Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.

ABSTRACT:

Background

Personalized medicine remains an unmet need in ovarian cancer due to its heterogeneous nature and complex immune microenvironments, which has gained increasing attention in the era of immunotherapy. A key obstacle is the lack of reliable biomarkers to identify patients who would benefit significantly from the therapy. While conventional clinicopathological factors have exhibited limited efficacy as prognostic indicators in ovarian cancer, multi-omics profiling presents a promising avenue for comprehending the interplay between the tumor and immune components. Here we aimed to leverage the individual proteomic and transcriptomic profiles of ovarian cancer patients to develop an effective protein-based signature capable of prognostication and distinguishing responses to im

SUBMITTER: Chen SF 

PROVIDER: S-EPMC11437962 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature